Sphere 3D Corp
Change company Symbol lookup
Select an option...
ANY Sphere 3D Corp
HMY Harmony Gold Mining Company Ltd
PLX Protalix Biotherapeutics Inc
BEDU Bright Scholar Education Holdings Ltd
USAS Americas Gold and Silver Corporation
AA Alcoa Corp
CRIS Curis Inc
APTO Aptose Biosciences Inc
RGLS Regulus Therapeutics Inc
IMH Impac Mortgage Holdings Inc
Go

Information Technology : Software | Small Cap Value
Based in Canada
Company profile

Sphere 3D Corp is a Canada-based company engaged in software development sector. The Company delivers data management, desktop and application virtualization solutions through hybrid cloud, cloud and on premise implementations by its global reseller network. The Company achieves this through a combination of containerized applications, virtual desktops, virtual storage and physical hyper-converged platforms. The Company’s products allow organizations to deploy a combination of public, private or hybrid cloud strategies while backing them up with the latest storage solutions. The Company has a portfolio of brands including RDX, Glassware 2.0, SnapCLOUD, SnapServer, SnapSync, NEO and V3 .

Closing Price
$2.68
Day's Change
-0.53 (-16.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.18
Day's Low
2.40
Volume
(Below Average)
Volume:
19,187,377

10-day average volume:
23,615,748
19,187,377

HIV Drugs Global Market Report 2021: COVID 19 Implications And Growth to 2030

6:40 am ET April 23, 2021 (Globe Newswire) Print

Reportlinker.com announces the release of the report "HIV Drugs Global Market Report 2021: COVID 19 Implications And Growth to 2030" - https://www.reportlinker.com/p06065174/?utm_source=GNW

H. Boehringer Sohn AG & Ko. KG), AbbVie, Inc., GlaxoSmithKline plc, and Mylan Pharmaceuticals.

The global hiv drugs market is expected to grow from $30.52 billion in 2020 to $31.28 billion in 2021 at a compound annual growth rate (CAGR) of 2.5%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $36.46 billion in 2025 at a CAGR of 3.9%.

The HIV drugs market consists of sales of Human Immunodeficiency Virus (HIV) drugs used for the treatment of HIV infection/AIDS. The market consists of revenue generated by the antiretroviral drug companies manufacturing the anti-retroviral drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs) for the treatment of HIV infection.

The novel corona virus outbreak has augmented the growth of global HIV drugs market.HIV drugs are repurposed to treat Covid 19 infections.

Currently, several countries are evaluating and using antiretroviral drugs (for instance lopinavir boosted with ritonavir (LPV/r)), for treating corona virus infection.

Side Effects of HIV Drugs have always been a major challenge in antiretroviral therapy.Antiretroviral drugs are used to treat HIV and AIDS as these drugs help lower viral load, control the growth of the virus, boosts the ability to fight infections, prevent HIV transmission to others and help stop or slow down symptoms.

These drugs come with both short-term side effects (diarrhea, difficulty in sleeping, dizziness, fatigue, headache, muscle pain) and long-term side effects (depression, diabetes, heart disease, insomnia). There are several side effects associated with the therapy, thus impacting the growth of the market.

Antiretroviral drugs market is increasingly implementing multi-class combination products for treatment of anti-retroviral therapy.Combination drugs combine multiple medications into one drug form.

Example for multiclass combination drugs or single-tablet regimens (STRs), include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo).Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others.

Multi-class Combination Products is the rising burden of HIV and new drug approval.According to WHO, around 690 000 people died from HIV in 2019.

Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets.

Increasing awareness among people regarding diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug market.HIV/AIDS is one of the most chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.

According to WHO, 26 million people were diagnosed with HIV/AIDS in 2020, whereas, 32.7 million people died of AIDS related illness at the end of 2019. The federal government agencies, and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care.

Read the full report: https://www.reportlinker.com/p06065174/?utm_source=GNW

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

https://ml.globenewswire.com/media/3e0b82c2-02d7-44c8-b22f-561e0f321f39/small/reportlinker-logo-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.